Education
About Us
Working with TipRanks
Follow Us
CASI Pharmaceuticals (CASI)
NASDAQ:CASI
RESEARCH TOOLSreports
| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 33.88M | $ 43.11M | $ 30.17M | $ 15.14M | $ 4.13M |
| Gross Profit | $ 20.05M | $ 27.28M | $ 17.61M | $ 5.63M | $ 196.00K |
| Operating Income | $ -25.08M | $ -26.49M | $ -35.28M | $ -33.31M | $ -39.99M |
| EBITDA | $ -21.54M | $ -24.07M | $ -32.75M | $ -31.35M | $ -37.43M |
| Net Income | $ -26.94M | $ -39.41M | $ -37.77M | $ -62.57M | $ -51.41M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 30.77M | $ 51.34M | $ 48.57M | $ 66.37M | $ 54.25M |
| Total Assets | $ 75.27M | $ 96.23M | $ 138.30M | $ 127.73M | $ 102.63M |
| Total Debt | $ 21.24M | $ 1.34M | $ 2.17M | $ 1.29M | $ 2.20M |
| Net Debt | $ 4.16M | $ -45.77M | $ -36.54M | $ -55.77M | $ -51.42M |
| Total Liabilities | $ 51.10M | $ 29.30M | $ 30.34M | $ 24.16M | $ 8.97M |
| Stockholders' Equity | $ 24.16M | $ 44.57M | $ 84.50M | $ 81.54M | $ 73.00M |
| Cash Flow | |||||
| Free Cash Flow | $ -22.21M | $ -26.70M | $ -42.34M | $ -45.21M | $ -37.26M |
| Operating Cash Flow | $ -19.97M | $ -21.09M | $ -26.84M | $ -25.89M | $ -23.24M |
| Investing Cash Flow | $ -9.67M | $ 31.16M | $ -20.69M | $ -20.72M | $ -28.06M |
| Financing Cash Flow | $ -907.00K | $ -3.27M | $ 29.64M | $ 47.15M | $ 22.05M |